We are live on ! Find out more
LMAT icon

LeMaitre Vascular

326 hedge funds and large institutions have $2.2B invested in LeMaitre Vascular in 2026 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 132 increasing their positions, 96 reducing their positions, and 49 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more repeat investments, than reductions

Existing positions increased: 132 | Existing positions reduced: 96

2.87% more ownership

Funds ownership: 97.16%100.04% (+2.9%)

4% less funds holding

Funds holding: 340326 (-14)

9% less capital invested

Capital invested by funds: $2.41B → $2.2B (-$219M)

20% less first-time investments, than exits

New positions opened: 39 | Existing positions closed: 49

43% less call options, than puts

Call options by funds: $259K | Put options by funds: $451K

50% less funds holding in top 10

Funds holding in top 10: 42 (-2)

Holders
326
Holders Change
-14
Holders Change %
-4.12%
% of All Funds
3.93%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
39
Increased
132
Reduced
96
Closed
49
Calls
$259K
Puts
$451K
Net Calls
-$192K
Net Calls Change
+$201K

LMAT Hedge Fund Activity: Q2 2026 in Review

326 of the 8,295 institutional investors tracked by Wall St. Rank reported a position in LeMaitre Vascular (LMAT) for Q2 2026, worth a combined $2.2B — down 9.1% from $2.41B a quarter earlier.

Sellers outnumbered buyers: 49 funds closed out of LMAT and 39 opened new positions — a net loss of 10 holders — while 96 trimmed existing stakes and 132 added.

The largest buyer was T. Rowe Price Associates, adding an estimated $47.2M. The largest seller was Driehaus Capital Management, exiting entirely with an estimated $21.5M sold.

  • 326 institutional investors held LeMaitre Vascular (LMAT) as of Q2 2026, down from 340 in Q1 2026.
  • Funds reported $2.2B of LeMaitre Vascular stock for Q2 2026, down 9.1% quarter-over-quarter.
  • 39 funds opened new LeMaitre Vascular positions in Q2 2026 and 49 closed out, a net change of -10 holders.
  • The largest LeMaitre Vascular buyer in Q2 2026 was T. Rowe Price Associates, an estimated $47.2M added.
  • The largest LeMaitre Vascular seller in Q2 2026 was Driehaus Capital Management, an estimated $21.5M sold.

Based on aggregated 13F filings for Q2 2026.